Covaxin
COVID-19 vaccine: Bharat Biotech submits Covaxin phase 3 trial data to DGCI, say reports
New Delhi/IBNS: Hyderabad-based drug manufacturer Bharat Biotech has submitted the phase three clinical trial data of its anti-COVID-19 vaccine, Covaxin, to the Drug Controller General of India (DGCI), media reports said.
A government official has confirmed it to a news agency.
As per reports, an expert committee is likely to meet to review the phase 3 trial data on Tuesday.
Covaxin is one the three anti-COVID-19 vaccines which are available in India.
Apart from the indigenous Covaxin, Oxford University's Covishield manufactured by the Serum Institute of India (SII) in India and Russia's Sputnik V are the two other vaccines, which are used by the country in the mass vaccination drive.
Meanwhile, more than 80 lakh people were vaccinated on Monday as the Centre started giving free vaccines to all aged 18 or more.
The central government in its new strategy has started procuring 75 per cent of vaccines from the manufactures and distributing them among all states free of cost.
India registered 42,640 new COVID-19 cases in the last 24 hours, revealed data released by the Ministry of Health on Tuesday.
During the past 24 hours, 1167 people died due to COVID-19.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
